Doctors prescribe Enhertu for certain types of breast, lung, and other cancers in ... In brief, the cancers are: HER2-positive breast cancer unresectable or metastatic HER2-low breast cancer ...

Enhertu already has seven FDA approvals across breast cancer, gastric cancer, non-small cell lung cancer (NSCLC), and advanced HER2-positive solid tumours, which have driven sales to more than $3. ...

Dr. Sara M. Tolaney discussed HER2-positive breast cancer, highlighting key trials, evolving treatment strategies, and the ...

Enhertu significantly improves overall survival in HER2-positive metastatic gastric cancer compared to ramucirumab and paclitaxel. DESTINY-Gastric04 is the first phase 3 trial showing Enhertu's ...

Enhertu is presently approved for advanced or metastatic HER2-positive gastric cancer, previously treated HER2-mutant metastatic non-small cell lung cancer and metastatic HER2-positive and HER2 ...

In February, AstraZeneca and Daiichi Sankyo teased the results of their pivotal trial of Enhertu in HER2 ... Breast cancer classed as HER2-positive - defined as an immunohistochemical (IHC ...

BB-1701 has survived Eisai’s decision not to option the HER2-directed antibody-drug conjugate. | BB-1701 has survived Eisai’s ...

Meanwhile, AZ and Daiichi just launched the four-arm phase 3 Destiny-Gastric05 trial to test Enhertu as a first-line treatment for HER2-positive stomach cancer. The study currently bears a primary ...